Recent Posts
Connect with:
Monday / May 20.
HomeminewsCooperVision Adds to Biofinity Lineup

CooperVision Adds to Biofinity Lineup

CooperVision Australia / New Zealand has announced the introduction of a new monthly replacement multifocal contact lens that provides both comfort and excellent vision. It was developed for the growing number of people with presbyopia.

The company has rounded out its Biofinity line of silicone hydrogel lenses with a multifocal lens that, according to clinical research and practitioner feedback, provided by the company1, makes fittings more successful and lenses more comfortable. Biofinity multifocal uses naturally wettable silicone, which retains water within the lens, therefore minimising dehydration.

As people get older, they’re not only prone to presbyopia, but their eyes can become drier, too. Because of that, the company says the “Biofinity multifocal lenses feature Aquaform Comfort Science, a naturally wettable material, and are approved for continuous wear up to 30 days / 29 nights. The material maximizes the multifocal lens for both moisture and oxygen, enabling high wettability for the presbyopic eye and ensuring that the lenses are comfortable throughout the day”.

In clinical studies, the company says “Biofinity multifocal lenses outperformed other brands in a range of measurements, including end-of-the-day comfort, vision quality, and intent to continue with a lens.

“In fact, patients rated Biofinity multifocal lenses as superior for overall satisfaction compared to both ACUVUE OASYS for PRESBYOPIA and PureVision Multi-Focal after two weeks of wear.”

CooperVision worked closely with eye-care practitioners to develop a new streamlined fitting process for its Balanced Progressive Technology approach. They say the fitting process makes it easier for eye-care practitioners to fit their patients and offers lens wearers an ideal combination of ease, comfort and eye health.

“I had much greater success with Balanced Progressive Technology than ever before when I followed the fitting steps to the letter,” said Jason Lake, OD of Eyecare Specialties in Warrensburg, Missouri. “The patient satisfaction was the highest I have encountered in any brand of multifocal contact lens and the visits were held to a minimum because the results were very predictable.”

CooperVision is incorporating Balanced Progressive Technology into Biofinity multifocal lenses, which “allows an individualised fit for each patient and each eye”.

The company has used Balanced Progressive Technology in previous multifocal contact lenses, but recently simplified the practice of fitting patients for multifocal lenses so they spend less time in the exam chair and have a greater likelihood of fitting success.

“One of the most important considerations for us in developing Biofinity multifocal was listening to eye-care professionals,” said Richard Clompus, OD, VP Global Professional Relations at CooperVision.

CooperVision learned that the way practitioners were practically prescribing lenses to patients with low ADDs meant some of the steps involved in fittings could be eliminated. The company modified its fitting protocol as a direct result of feedback from professionals.

“Collaborating with the practitioners who work directly with lens wearers every day and understanding that every eye is unique-that’s how we’re able to bring outstanding new products to market time and again,” Clompus said.

CooperVision further validated the new fitting protocol through clinical study and tested it with eye-care practitioners, including Mile Brujic, OD of Premier Vision Group in Bowling Green, Ohio.

“It is a remarkably comfortable lens and this is important for our contact lens-wearing presbyopes,” Brujic said. “The sophisticated multifocal lens design makes it a versatile, uniquely-designed lens for even your most demanding presbyopic patients.”

The Biofinity multifocal is available in sphere powers of +6.00 D to -8.00D and in four ADD powers (+1.00, +1.50, +2.00, +2.50).

Biofinity is currently CooperVision’s fastest growing brand.

For more information go to: www.biofinitymultifocal.eu/en/practitioner/

1. Data based on 2010 CooperVision studies conducted in the U.S. Research results are on file.